Literature DB >> 17369375

Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target?

Paul Rutgeerts1, Severine Vermeire, Gert Van Assche.   

Abstract

The main goal of treatment for Crohn's disease and ulcerative colitis has always been the induction and maintenance of symptomatic improvement or at best remission. It has been shown by many studies that the long-term outcome of these diseases is not influenced by standard treatments and that the need for surgery is not decreasing in this population over the years. There is recent evidence that with immunosuppression and treatment with infliximab long-term healing of the bowel can be achieved and that this affects the outcome of both Crohn's disease and ulcerative colitis. We propose that future studies should focus on healing and disease course as primary outcome measures.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17369375      PMCID: PMC1856849          DOI: 10.1136/gut.2005.088732

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  15 in total

1.  Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease.

Authors:  Paul Rutgeerts; Brian G Feagan; Gary R Lichtenstein; Lloyd F Mayer; Stefan Schreiber; Jean Frederic Colombel; Daniel Rachmilewitz; Douglas C Wolf; Allan Olson; Weihang Bao; Stephen B Hanauer
Journal:  Gastroenterology       Date:  2004-02       Impact factor: 22.682

2.  Endoscopic and histologic healing of Crohn's (ileo-) colitis with azathioprine.

Authors:  G D'Haens; K Geboes; P Rutgeerts
Journal:  Gastrointest Endosc       Date:  1999-11       Impact factor: 9.427

3.  Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Thérapeutique des Affections Inflammatoires Digestives.

Authors:  R Modigliani; J Y Mary; J F Simon; A Cortot; J C Soule; J P Gendre; E Rene
Journal:  Gastroenterology       Date:  1990-04       Impact factor: 22.682

4.  Natalizumab induction and maintenance therapy for Crohn's disease.

Authors:  William J Sandborn; Jean Frédéric Colombel; Roberts Enns; Brian G Feagan; Stephen B Hanauer; Ian C Lawrance; Remo Panaccione; Martin Sanders; Stefan Schreiber; Stephan Targan; Sander van Deventer; Ronald Goldblum; Darrin Despain; Gary S Hogge; Paul Rutgeerts
Journal:  N Engl J Med       Date:  2005-11-03       Impact factor: 91.245

5.  A randomized, double-blind, controlled withdrawal trial in Crohn's disease patients in long-term remission on azathioprine.

Authors:  Marc Lémann; Jean-Yves Mary; Jean-Frédéric Colombel; Bernard Duclos; Jean-Claude Soule; Eric Lerebours; Robert Modigliani; Yoram Bouhnik
Journal:  Gastroenterology       Date:  2005-06       Impact factor: 22.682

6.  Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires du Tube Digestif (GETAID).

Authors:  J Y Mary; R Modigliani
Journal:  Gut       Date:  1989-07       Impact factor: 23.059

7.  Long-term evolution of disease behavior of Crohn's disease.

Authors:  Jacques Cosnes; Stéphane Cattan; Antoine Blain; Laurent Beaugerie; Franck Carbonnel; Rolland Parc; Jean-Pierre Gendre
Journal:  Inflamm Bowel Dis       Date:  2002-07       Impact factor: 5.325

8.  Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD.

Authors:  Marco Daperno; Geert D'Haens; Gert Van Assche; Filip Baert; Philippe Bulois; Vincent Maunoury; Raffaello Sostegni; Rodolfo Rocca; Angelo Pera; Annemie Gevers; Jean-Yves Mary; Jean-Frédéric Colombel; Paul Rutgeerts
Journal:  Gastrointest Endosc       Date:  2004-10       Impact factor: 9.427

9.  Glucocorticoid treatment in ileal Crohn's disease: relief of symptoms but not of endoscopically viewed inflammation.

Authors:  G Olaison; R Sjödahl; C Tagesson
Journal:  Gut       Date:  1990-03       Impact factor: 23.059

10.  Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease.

Authors:  R A Kozarek; D J Patterson; M D Gelfand; V A Botoman; T J Ball; K R Wilske
Journal:  Ann Intern Med       Date:  1989-03-01       Impact factor: 25.391

View more
  84 in total

1.  Colon capsule endoscopy: Advantages, limitations and expectations. Which novelties?

Authors:  Maria Elena Riccioni; Riccardo Urgesi; Rossella Cianci; Alessandra Bizzotto; Cristiano Spada; Guido Costamagna
Journal:  World J Gastrointest Endosc       Date:  2012-04-16

2.  Remission induction and maintenance effect of probiotics on ulcerative colitis: a meta-analysis.

Authors:  Li-Xuan Sang; Bing Chang; Wen-Liang Zhang; Xiao-Mei Wu; Xiao-Hang Li; Min Jiang
Journal:  World J Gastroenterol       Date:  2010-04-21       Impact factor: 5.742

Review 3.  Mucosal healing in inflammatory bowel disease: where do we stand?

Authors:  Christina Ha; Asher Kornbluth
Journal:  Curr Gastroenterol Rep       Date:  2010-12

Review 4.  Clinical implications of mucosal healing for the management of IBD.

Authors:  Guillaume Pineton de Chambrun; Laurent Peyrin-Biroulet; Marc Lémann; Jean-Frédéric Colombel
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2009-12-01       Impact factor: 46.802

Review 5.  Crohn's disease: evidence for involvement of unregulated transcytosis in disease etio-pathogenesis.

Authors:  Jay Pravda
Journal:  World J Gastroenterol       Date:  2011-03-21       Impact factor: 5.742

6.  Integrated Analysis of Biopsies from Inflammatory Bowel Disease Patients Identifies SAA1 as a Link Between Mucosal Microbes with TH17 and TH22 Cells.

Authors:  Mei San Tang; Rowann Bowcutt; Jacqueline M Leung; Martin J Wolff; Uma M Gundra; David Hudesman; Lisa B Malter; Michael A Poles; Lea Ann Chen; Zhiheng Pei; Antonio G Neto; Wasif M Abidi; Thomas Ullman; Lloyd Mayer; Richard A Bonneau; Ilseung Cho; Pʼng Loke
Journal:  Inflamm Bowel Dis       Date:  2017-09       Impact factor: 5.325

7.  Characterization of lymphoid follicles with red ring signs as first manifestation of early Crohn's disease by conventional histopathology and confocal laser endomicroscopy.

Authors:  Ekaterina Krauss; Abbas Agaimy; Helmut Neumann; Ulrike Schulz; Hermann Kessler; Arndt Hartmann; Markus F Neurath; Martin Raithel; Jonas Mudter
Journal:  Int J Clin Exp Pathol       Date:  2012-05-23

8.  Histological healing favors lower risk of colon carcinoma in extensive ulcerative colitis.

Authors:  Burton I Korelitz; Keith Sultan; Megha Kothari; Leo Arapos; Judy Schneider; Georgia Panagopoulos
Journal:  World J Gastroenterol       Date:  2014-05-07       Impact factor: 5.742

Review 9.  Are we giving biologics too much time? When should we stop treatment?

Authors:  Edouard Louis; J Belaiche; C Reenaers
Journal:  World J Gastroenterol       Date:  2008-09-28       Impact factor: 5.742

10.  Dietary phenethylisothiocyanate attenuates bowel inflammation in mice.

Authors:  Moul Dey; Peter Kuhn; David Ribnicky; Vummidigiridhar Premkumar; Kenneth Reuhl; Ilya Raskin
Journal:  BMC Chem Biol       Date:  2010-04-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.